Exploring SciSparc Ltd. (SPRC) Investor Profile: Who’s Buying and Why?

You're looking at SciSparc Ltd. (SPRC) and wondering why a company with a current market capitalization (market cap) of just $3.93 million-a nano-cap stock-still draws institutional interest, right? Honestly, the near-term financials look tough: the half-year report ending June 30, 2025, showed sales of only $0.461 million against a net loss of $9.33 million. That's a massive cash burn. Still, major players like UBS Group AG and Bank Of America Corp /De/ have recently filed positions, even if total institutional ownership sits at a defintely low 0.5% of the float. So, what are these sophisticated investors actually buying? They aren't betting on 2025 revenue; they are making a highly speculative bet on the intellectual property (IP) pipeline, like the November 2025 announcement of an Israeli patent application for a novel non-hallucinogenic neuroplastogen treatment for depression. Are they seeing a clear path to monetization for this cannabinoid-focused pharma, or is this a classic high-risk, high-reward biotech play where a single patent is worth more than the entire current market cap? Let's break down the investor profile to see who is buying and what valuation model they are truly using.

Who Invests in SciSparc Ltd. (SPRC) and Why?

SciSparc Ltd. (SPRC) has a highly unusual investor profile for a NASDAQ-listed company, driven by a speculative, high-growth narrative that shifted dramatically in 2025. The core takeaway is that this is overwhelmingly a retail-driven stock, with institutional money playing a very minor, often short-term, role. This setup means the stock price is defintely more susceptible to news, momentum, and short-term trading dynamics.

You are looking at a stock where nearly all the ownership is in the hands of individual investors, not the big funds. That makes it volatile. As of late 2025, institutional ownership was exceptionally low, sitting at only 0.48% of total shares outstanding. This contrasts sharply with the biotech sector average, which typically sees much higher institutional participation. The vast majority-around 96.22%-of the float is held by retail investors. This is a critical factor for anyone assessing SPRC's risk profile.

Key Investor Types and Their Footprint

The investor base for SciSparc Ltd. (SPRC) is a clear dichotomy between a small number of large institutions and a massive crowd of individual retail investors. This split informs everything about the stock's trading behavior. Here's the quick math on the institutional side:

• Retail Investors: Hold the lion's share, focused on the potential for a massive payout from a drug pipeline success or a strategic pivot. They are the primary source of liquidity and volatility.
• Institutional Investors: A small group of firms, including banks and hedge funds, hold a minimal stake. As of September 30, 2025, the total institutional shares held were only 7,786.
• Hedge Funds: Activity has been mixed, which is typical for a micro-cap stock. You see firms like Renaissance Technologies Llc selling out, while others like UBS Group AG are building a position.

The institutional positions are small, but their movements can still signal a shift. For instance, UBS Group AG held 5,408 shares as of the end of Q3 2025, and Bank Of America Corp /De/ held 1,366 shares. That's not a vote of confidence in the traditional sense, but it shows some large players are keeping a small, speculative toe in the water.

Investment Motivations: Catalysts, Not Cash Flow

Investors are buying SciSparc Ltd. (SPRC) for its potential, not its current financial performance. The company is a clinical-stage pharmaceutical firm, meaning profits are years away, if they ever materialize. The half-year earnings report for the period ending June 30, 2025, showed sales of only $0.461 million and a net loss of $9.33 million. No one is buying SPRC for dividends; they are buying for massive growth.

The key motivations are a series of high-impact, high-risk strategic pivots announced in 2025:

• Pharma Pipeline: The original draw is the potential of its cannabinoid-based therapies for CNS disorders, like the new patent application for a combination therapy targeting depression announced in November 2025. This is the core long-term growth story.
• Strategic Diversification: The merger with AutoMax Motors in Q3 2025 to enter the electric vehicle (EV) market was a huge catalyst, causing the stock to soar by 175.0% at the time. This move is seen as a way to enhance shareholder value by moving into a high-growth sector.
• Technology Leap: The launch of a quantum computing initiative for 3D protein modeling in Q3 2025 also fueled a rally, with the stock surging 45.5% in premarket trading. This positions the company as a deep-tech innovator, broadening its appeal beyond traditional pharma.

These are all high-risk bets on future intellectual property (IP) and strategic execution. You can read more about the long-term vision here: Mission Statement, Vision, & Core Values of SciSparc Ltd. (SPRC).

Investment Strategies: The Momentum Trade

Given the low institutional ownership and high volatility, the dominant strategy for SciSparc Ltd. (SPRC) is short-term trading and speculation, often called a momentum trade. The stock's price movements are less about Discounted Cash Flow (DCF) valuation and more about the news cycle.

• Short-Term Trading: Traders are jumping on the stock following major news announcements-the merger, the quantum computing plan, or a new patent-to capitalize on the immediate, sharp price spikes.
• Speculative Growth Holding: Retail investors, in particular, are holding for the long-term, believing one of the company's many high-risk bets (pharma, EV, quantum) will pay off handsomely. It's a classic high-risk, high-reward approach.
• Short Selling: The stock is also a target for short sellers, who bet the price will fall. The short sale ratio was high at 21.41% as of November 18, 2025, which can lead to dramatic short squeezes when positive news hits. This high short interest is a clear signal of the market's divided opinion on the company's long-term viability.

The technical indicators as of November 2025 lean bearish, with a falling trend, but the high short interest suggests the potential for a sharp, upward reversal if another major catalyst emerges. It's a battleground stock. Your next step should be to monitor the short interest data alongside the clinical trial and patent news flow. Finance: Track the daily short volume against the average trading volume to gauge the pressure.

Institutional Ownership and Major Shareholders of SciSparc Ltd. (SPRC)

You need to know who the major players are in SciSparc Ltd. (SPRC) because institutional money signals confidence, or lack thereof, in a small-cap biotech firm. The direct takeaway here is that institutional ownership in SPRC is extremely low, sitting at just 0.48% of total shares outstanding as of the latest filings, which tells you the stock is overwhelmingly driven by retail investors and short-term trading.

This tiny percentage of institutional holding, coupled with a small market capitalization of around $3.93 million as of November 2025, means any significant institutional move-even a small one-can cause disproportionate stock price volatility.

Top Institutional Investors: Who's Holding the Line?

The institutional landscape for SciSparc Ltd. is notably thin, with only a handful of firms reporting positions. For the 2025 fiscal year's third quarter (Q3 2025), the largest institutional holders are primarily financial giants taking small, often tactical, positions.

Here's the quick math on the top active positions reported in Q3 2025, which totaled 7,786 shares across all institutional holders:

• UBS Group AG: Held 5,408 shares, representing the largest stake.
• Bank of America Corp /DE/: Held 1,366 shares.
• Valley National Advisers Inc.: Held 1,000 shares.

These are not the massive, long-term block holdings you see in a BlackRock or Vanguard position; they are small, tactical bets in a highly speculative space. The total value of these holdings is negligible compared to the firms' overall assets, but for SPRC, they represent nearly half of the institutional float. For more on the company's focus, you can review their Mission Statement, Vision, & Core Values of SciSparc Ltd. (SPRC).

Shifts in Ownership: The Q3 2025 Buying and Selling

Institutional activity in Q3 2025 was a mixed bag, showing a definite push and pull. We saw 2 institutional investors adding shares and 7 decreasing their positions in the most recent quarter, indicating more institutions are reducing exposure than increasing it.

The most notable moves in Q3 2025 show a few firms establishing or significantly increasing their stakes, while others are hitting the exit. For instance, UBS Group AG increased its position by 2,097 shares, a 63.334% jump. In a more dramatic move, Bank of America Corp /DE/ added 1,364 shares, which represented a massive percentage increase from a tiny base.

But still, the selling was significant. Renaissance Technologies LLC, a major quantitative hedge fund, completely sold out of their position, removing 2,070 shares in Q3 2025. Similarly, SBI Securities Co., Ltd. reduced its holding by 96.883%, removing 373 shares. This net selling pressure from several institutional players is a red flag for a small-cap stock.

Impact of Institutional Investors: Volatility and Validation

In a company like SciSparc Ltd., institutional investors play a unique role because their ownership is so small. They are not setting the long-term strategy or demanding board seats; they are acting as a short-term validation signal or a source of volatility.

The key impact is twofold:

• Validation Signal: When a name like UBS or Bank of America takes a position, it offers a brief moment of institutional validation, suggesting their analysts see something of value, likely tied to the company's clinical-stage pharmaceutical developments in cannabinoid pharmaceuticals.
• Volatility Amplifier: With only 0.48% institutional ownership, the stock is highly susceptible to the whims of retail investors and short-term traders. When an institution buys or sells, even a few thousand shares, the low trading volume and small float mean the price impact is amplified. It's defintely a high-risk, high-volatility trade.

The larger strategic concern for SPRC, which institutional investors are watching closely, is the Nasdaq compliance issue. The company was given a deadline of July 14, 2025, to maintain a bid price of at least $1.00 per share, a hurdle that often requires a reverse stock split (a reverse split was announced effective July 3, 2025). Institutional buying interest will remain muted until the company demonstrates sustained compliance and tangible progress in its pipeline.

Next Step: Review the latest 13F filings for Q4 2025 when they become available to see if the net selling trend has reversed or intensified.

Key Investors and Their Impact on SciSparc Ltd. (SPRC)

You're looking at SciSparc Ltd. (SPRC) and trying to figure out if the big money is buying in or bailing out. The direct takeaway is that institutional interest remains low, which is typical for small-cap biotech, but the few major players who are invested showed significant, albeit small-scale, trading activity in the third quarter of 2025.

The investor profile for SciSparc Ltd. is heavily skewed toward retail investors, who hold roughly 78.00% of the company's shares. This leaves institutional ownership-the hedge funds, banks, and major money managers-at a very low level, around 0.48% of the total shares outstanding as of the end of the third quarter of 2025. This low institutional float means the stock price is defintely more susceptible to volatility and individual investor sentiment, not the steady hand of a BlackRock-style fund.

Here's a look at the largest reported institutional holders and their positions as of September 30, 2025, following the company's 1-for-21 reverse share split in July 2025. The total institutional shares held were a mere 7,786, reflecting the small-cap, high-risk nature of the stock.

The influence of these investors is less about demanding board seats and more about signaling conviction. For instance, the total value of all institutional holdings was only a few thousand dollars, so no single institution has the clout to dictate corporate strategy. However, their collective action does matter. The fact that UBS Group AG and Bank Of America Corp /De/ significantly increased their positions-by 63.334% and 68200% respectively-suggests a calculated, if small, bet on the company's future, likely prompted by the low share price post-split.

On the flip side, the complete exit of a quantitative fund like Renaissance Technologies Llc, which sold its entire position of 2,070 shares, suggests their models no longer see a favorable risk/reward setup. This kind of move can trigger a downward pressure on the stock, especially in a thinly traded name like SciSparc Ltd. (SPRC). It's a classic example of a 'smart money' exit that retail investors should watch closely.

Recent major corporate moves, which require shareholder approval, also show where investor influence is focused:

• Reverse Share Split: Shareholders approved a 1-for-21 reverse split, effective July 3, 2025, to maintain Nasdaq listing compliance.
• Merger Approvals: Shareholders approved the merger with a leading parallel vehicle importer in Israel and the sale of the majority-owned subsidiary MitoCareX in August and October 2025, respectively.
• Strategic Direction: The approval of these measures shows investors are supporting the company's pivot toward new opportunities, like the quantum-powered 3D protein modeling initiative, and its overall strategic direction. You can read more about the company's forward-looking plans here: Mission Statement, Vision, & Core Values of SciSparc Ltd. (SPRC).

What this estimate hides is the extreme volatility; the stock price was around $3.25 per share as of October 31, 2025, but the 52-week high was $8.90, showing the dramatic swings that come with low institutional oversight and a small public float. Your action here is to recognize that with only 7,786 total institutional shares, the stock is driven by news and retail momentum, not deep institutional analysis.

Market Impact and Investor Sentiment

You need a clear picture of who is holding SciSparc Ltd. (SPRC) and why, especially with the stock's recent volatility and strategic pivots. The direct takeaway is this: while institutional money is net-reducing its exposure, the stock's price movements in 2025 have been overwhelmingly driven by positive reactions to major corporate restructuring, specifically the move into the electric vehicle sector and the pharma portfolio transfer. The current technical sentiment, however, remains defintely bearish.

The company's strategic shift-moving its pharma assets into a new entity while focusing on the AutoMax Motors merger-is what's driving the narrative. This is a classic biotech-to-something-else pivot, and it creates a split investor base: the short-term traders chasing the merger news, and the long-term holders who are either exiting or waiting for the new business model to stabilize.

Investor Sentiment: A Bearish Consensus on Technicals

Honesty is key here: the overall technical sentiment for SciSparc Ltd. (SPRC) as of November 2025 is Bearish. My review of technical indicators shows a clear bias: 21 signals are bearish, compared to only 5 signaling bullish. The Fear & Greed Index is sitting at 39 (Fear), which tells you that retail and short-term traders are nervous. This isn't surprising for a micro-cap stock undergoing a massive business transformation and facing Nasdaq compliance issues.

Institutional activity in the third quarter of 2025 (Q3 2025) shows a net decrease in the number of institutions holding shares. You see mixed signals, but the overall trend is one of caution:

• UBS GROUP AG added 2,097 shares, an increase of 63.3%, valued at an estimated $12,665.
• BANK OF AMERICA CORP /DE/ made a substantial percentage increase, adding 1,364 shares, which is a 68200.0% change, valued at an estimated $8,238.
• Conversely, major players like RENAISSANCE TECHNOLOGIES LLC and TWO SIGMA SECURITIES, LLC completely sold out their positions in Q3 and Q2 2025, respectively, indicating a flight from the stock's previous business model.

It's a low-float stock with a small number of institutional owners, so any single move looks dramatic. The total institutional shares held are only around 7,786 as of Q3 2025. That's a tiny float, so one big trade can move the needle fast.

Recent Market Reactions to Strategic Moves

The market has responded with extreme volatility to SciSparc Ltd.'s corporate actions in 2025, which is typical for a stock with a low float and high-impact news. The company executed a 1-for-21 reverse share split on July 3, 2025, which reduced the outstanding share count from approximately 11.2 million to about 534,600, aimed at regaining Nasdaq compliance. This move often causes a short-term price jump but doesn't fix underlying business issues.

The real market excitement came from the strategic pivots:

• September 17, 2025: The stock surged by 175.0% in pre-market trading following the announcement of the AutoMax Motors merger approval, signaling investor enthusiasm for the shift into the electric vehicle market.
• September 25, 2025: Shares trended up by 66.06% after a court stay on the merger proceedings, which was interpreted as a positive step toward closing the deal.

This tells you that investors are buying the story of diversification. The company's financial health around that time showed a reported revenue of $1.31 million and a cash balance of $1.54 million, so the strategic moves are essential for growth. The shares traded at $3.25 per share on October 31, 2025, showing a 33.61% decline from a year prior, but the news-driven spikes show a willingness to buy on catalysts.

Analyst Perspectives and Key Investor Impact

Analyst coverage is thin, which is another risk factor for you to consider. Based on the limited Wall Street coverage, the consensus rating for SciSparc Ltd. is a simple Sell. One analyst has even issued a price target of $0.00, predicting a -100.00% downside from the time of their report, which is a harsh assessment of the company's long-term viability under its former structure.

However, you also have a forecast suggesting an average annualized price of $2.48 for December 2025, which is closer to the current trading range. The key investor impact right now isn't a single large fund but the company itself, through its corporate actions. The transfer of the advanced clinical-stage pharmaceutical portfolio, valued at approximately $11.6 million, into a new entity (NeuroThera Labs Inc.) allows SciSparc Ltd. to maintain a controlling interest of approximately 75% while separating the high-risk, long-cycle pharma development from the new, potentially faster-growth automotive venture.

Here's the quick math on the strategic separation:

This financial engineering is meant to make the new SciSparc Ltd. a cleaner, more attractive investment vehicle focused on the new business, but the market is still waiting for proof of execution. For a deeper dive into the company's underlying numbers, you should check out Breaking Down SciSparc Ltd. (SPRC) Financial Health: Key Insights for Investors.

Your next concrete step is to track the closing of the AutoMax Motors merger and the first financial reports from the new NeuroThera Labs entity. Those two events will override any technical indicator or old analyst rating.